The 30-year FRM averaged 6.81 percent as of November 27, 2024, down from last week when it averaged 6.84 percent. A year ago ...
"The Global State of Tobacco Harm Reduction 2024: A Situation Report" says safer nicotine products, such as nicotine vapes, ...
For assistance finding and collaborating with Taiwan's leading innovators, please visit: Or email: [email protected ...
Digital Ally, Inc. (Nasdaq: DGLY) (the “Company”) today announced it received a delinquency notification letter from Nasdaq on November 25, 2024, which indicated that the Company was not in compliance ...
The Company has also scheduled a conference call for Friday, December 13, 2024, at 11:00 a.m. ET (10:00 a.m. CT) to discuss the release. A link to the live audio webcast will be available on Quanex’s ...
Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today ...
Fundamental Global Inc. (Nasdaq: FGF) (the “Company” or "Fundamental Global"), formerly known as FG Financial Group, Inc., today announced that it has declared a quarterly cash dividend on its 8.00% ...
The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.
The panel discussion will be accessible via webcast through a link on the Investor Events and Presentations section of the Coherus website: Coherus Contact Information: For Investors: Jodi Sievers VP ...
Govorestat is a central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) being developed for the treatment of multiple rare diseases including Classic Galactosemia, Sorbitol ...
Revolutionary Dual-Function Design The Akluer 520 Dual-Sided Treadmill combines the best of both worlds, offering a treadmill ...
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that ...